Patents by Inventor Roger G. Little

Roger G. Little has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for killing gram-negative bacteria with biologically active peptides from functional domains of bacterial/permeability-increasing protein
    Patent number: 6495516
    Abstract: The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof, and variants of the sequence or subsequence thereof, having at least one of the BPI biological activities, such as heparin binding, heparin neutralization, LPS binding, LPS neutralization or bactericidal activity. The invention provides peptides and pharmaceutical compositions of such peptides for a variety of therapeutic uses.
    Type: Grant
    Filed: February 21, 2001
    Date of Patent: December 17, 2002
    Assignee: Xoma Technology Ltd.
    Inventor: Roger G. Little, II
  • Identification of novel antimicrobial agents using membrane potential indicator dyes
    Patent number: 6455271
    Abstract: Novel screening methods for identifying antimicrobial agents involving use of membrane potential indicator dyes are provided.
    Type: Grant
    Filed: July 27, 2000
    Date of Patent: September 24, 2002
    Assignee: XOMA Technology, Ltd
    Inventors: Roger G. Little, II, Susan Abrahamson, Peter Wong
  • Identification of novel antimicrobial agents using metabolic oxidation-reduction indicator dyes
    Patent number: 6436660
    Abstract: Novel screening methods for identifying antimicrobial agents involving use of metabolic oxidation-reduction indicator dyes are provided.
    Type: Grant
    Filed: April 6, 2000
    Date of Patent: August 20, 2002
    Assignee: XOMA Technology Ltd.
    Inventor: Roger G. Little, II
  • Therapeutic derivative compounds derived from domain II of bactericidal/permeability-increasing protein
    Patent number: 6423825
    Abstract: The present invention relates generally to small derivatized peptide-based constructs and their therapeutic uses. The sequences of these derivatized peptide-based constructs are based on a reverse subsequence derived from Domain II of bactericidal/permeability-increasing protein (BPI).
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: July 23, 2002
    Assignee: Xoma Technology Ltd.
    Inventors: Roger G. Little, II, Jong-Jye Lin, J. G. Kinyua Gikonyo
  • Therapeutic uses of bactericidal/permeability increasing (BPI) protein products
    Publication number: 20020090368
    Abstract: The present invention provides therapeutic methods for treatment of conditions including the neutralization of the anti-coagulant activity of heparin, inhibition of angiogenesis, tumor and endothelial cell proliferation, and treatment of chronic inflammatory diseases by administration of bactericidal/permeability-increasing (BPI) protein products.
    Type: Application
    Filed: August 27, 2001
    Publication date: July 11, 2002
    Applicant: XOMA Corporation
    Inventor: Roger G. Little
  • Anti-fungal peptides
    Publication number: 20020077298
    Abstract: The present invention relates generally to anti-fungal peptides derived from or based on Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI) and therapeutic uses of such peptides.
    Type: Application
    Filed: June 14, 2001
    Publication date: June 20, 2002
    Applicant: XOMA Corporation
    Inventors: Roger G. Little, Edward Lim, Mitchell B. Fadem
  • Agents and methods for inhibiting F1/F0 ATPase
    Patent number: 6376211
    Abstract: Novel methods of identifying antimicrobial and anti-proliferative agents and therapeutic uses are provided.
    Type: Grant
    Filed: April 6, 2000
    Date of Patent: April 23, 2002
    Assignee: XOMA Technology Ltd.
    Inventors: Roger G. Little, II, Susan Abrahamson
  • Derivative compounds derived from or based on bactericidal/permeability-increasing protein
    Patent number: 6355616
    Abstract: The present invention relates generally to derivatized antifungal compounds that are peptide-based constructs derived from or based on subsequences of Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI) and in vivo or in vitro uses of such compounds.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: March 12, 2002
    Assignee: Xoma (US) Technology Ltd.
    Inventors: Roger G. Little, II, Jong-Jye Lin, J. G. Kinyua Gikonyo
  • Therapeutic uses of bactericidal/permeability-increasing protein dimer products
    Patent number: 6277821
    Abstract: Improved therapeutic compositions, methods and uses of bactericidal/permeability-increasing protein (BPI) products involve use of dimeric forms of BPI protein product monomers characterized by enhanced in vivo biological activity. Preferred formulations include 50 percent or more by weight dimeric product and preferred therapeutic uses include endotoxin neutralization and heparin neutralization.
    Type: Grant
    Filed: December 30, 1998
    Date of Patent: August 21, 2001
    Assignee: Xoma Corporation
    Inventors: William Steve Ammons, Roger G. Little
  • Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
    Patent number: 6228834
    Abstract: The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof, and variants of the sequence or subsequence thereof, having at least one of the BPI biological activities, such as heparin binding, heparin neutralization, LPS binding, LPS neutralization or bactericidal activity. The invention provides peptides and pharmaceutical compositions of such peptides for a variety of therapeutic uses.
    Type: Grant
    Filed: June 8, 1998
    Date of Patent: May 8, 2001
    Assignee: Xoma Corporation
    Inventor: Roger G. Little, II
  • Anti-fungal peptides
    Patent number: 6156730
    Abstract: The present invention relates generally to anti-fungal peptides derived from or based on Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI) and in vivo or in vitro uses of such peptides.
    Type: Grant
    Filed: January 8, 1999
    Date of Patent: December 5, 2000
    Assignee: Xoma Corporation
    Inventors: Roger G. Little, II, Edward Lim, Mitchell B. Fadem
  • Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
    Patent number: 6153730
    Abstract: The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof, and variants of the sequence or subsequence thereof, having at least one of the BPI biological activities, such as heparin binding, heparin neutralization, LPS binding, LPS neutralization or bactericidal activity. The invention provides peptides and pharmaceutical compositions of such peptides for a variety of therapeutic uses.
    Type: Grant
    Filed: December 31, 1998
    Date of Patent: November 28, 2000
    Assignee: Xoma Corporation
    Inventor: Roger G. Little, II
  • Identification of novel antimicrobial agents using membrane potential indicator dyes
    Patent number: 6143516
    Abstract: Novel screening methods for identifying antimicrobial agents involving use of membrane potential indicator dyes are provided.
    Type: Grant
    Filed: September 24, 1999
    Date of Patent: November 7, 2000
    Assignee: XOMA Technology Ltd.
    Inventors: Roger G. Little, II, Susan Abrahamson, Peter Wong
  • Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (BPI) protein product and antibiotic
    Patent number: 6140306
    Abstract: The present invention relates to methods and compositions for treating gram-negative bacterial infections, using BPI protein products. Co-treatment, or concurrent administration, of BPI protein product with an antibiotic in treatment of gram-negative bacterial infections improves the therapeutic effectiveness of the antibiotic, including increasing antibiotic susceptibility of gram-negative bacteria and reversing resistance of the bacteria to antibiotics.
    Type: Grant
    Filed: June 3, 1996
    Date of Patent: October 31, 2000
    Assignee: Xoma Corporation
    Inventors: Lewis H. Lambert, Jr., Roger G. Little, II
  • Anti-gram-positive bacterial methods and materials
    Patent number: 6054431
    Abstract: The present invention relates to methods of treating gram-positive bacterial infections by administration of a BPI protein product alone, or in combination with an antibiotic. BPI protein product alone has a bactericidal or growth inhibitory effect on selected gram-positive organisms. BPI protein product also increases the susceptibility of gram-positive organisms to antibiotics and can even reverse resistance of gram-positive organisms to antibiotic.
    Type: Grant
    Filed: July 20, 1998
    Date of Patent: April 25, 2000
    Assignee: XOMA Corporation
    Inventors: Arnold Horwitz, Lewis H. Lambert, Jr., Roger G. Little, II
  • Anti-fungal peptides
    Patent number: 5858974
    Abstract: The present invention relates generally to anti-fungal peptides derived from or based on Domain III (amino aids 142-169) of bactericidal/permeability-increasing protein (BPI) and in vivo or in vitro uses of such peptides.
    Type: Grant
    Filed: March 21, 1996
    Date of Patent: January 12, 1999
    Assignee: XOMA Corporation
    Inventors: Roger G. Little, II, Edward Lim, Mitchell B. Fadem
  • Therapeutic uses of bactericidal/permeability-increasing protein dimer products
    Patent number: 5856302
    Abstract: Improved therapeutic compositions, methods and uses of bactericidal/permeability-increasing protein (BPI) products involve use of dimeric forms of BPI protein product monomers characterized by enhanced in vivo biological activity. Preferred formulations include 50 percent or more by weight dimeric product and preferred therapeutic uses include endotoxin neutralization and heparin neutralization.
    Type: Grant
    Filed: December 16, 1996
    Date of Patent: January 5, 1999
    Assignee: XOMA Corporation
    Inventors: William Steve Ammons, Roger G. Little
  • Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
    Patent number: 5856438
    Abstract: The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof, and variants of the sequence or subsequence thereof, having at least one of the BPI biological activities, such as heparin binding, heparin neutralization, LPS binding, LPS neutralization or bactericidal activity. The invention provides peptides and pharmaceutical compositions of such peptides for a variety of therapeutic uses.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 5, 1999
    Assignee: XOMA Corporation
    Inventor: Roger G. Little, II
  • Therapeutic uses of bactericidal/permeability increasing protein products
    Patent number: 5854214
    Abstract: The present invention provides therapeutic methods for treatment of conditions including the neutralization of the anti-coagulant activity of heparin, inhibition of angiogenesis, tumor and endothelial cell proliferation, and treatment of chronic inflammatory diseases by administration of bactericidal/permeability-increasing (BPI) protein products.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 29, 1998
    Assignee: XOMA Corporation
    Inventor: Roger G. Little, II
  • Therapeutic uses of bactericidal/permeability increasing protein products
    Patent number: 5837678
    Abstract: The present invention provides therapeutic methods for treatment of conditions including the neutralization of the anti-coagulant activity of heparin, inhibition of angiogenesis, tumor and endothelial cell proliferation, and treatment of chronic inflammatory diseases by administration of bactericidal/permeability-increasing (BPI) protein products.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 17, 1998
    Assignee: XOMA Corporation
    Inventor: Roger G. Little, II